886496-83-9

Usage

Chemical Properties

Off-white powder

Upstream product

• 328-68-7 3-amino-5-(trifluoromethyl)benzoic acid 
• 328-80-3 3-nitro-5-trifluoromethyl-benzoic acid 
• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 53985-49-2 3-chloro-5-(trifluoromethyl)benzoic acid 

Downstream Products

• 1214361-12-2 methyl 3-chloro-5-(trifluoromethyl)benzoate 
• 1125812-58-9 1-(3-chloro-5-(trifluoromethyl)phenyl)-2,2,2-trifluoroethan-1-one 
• 1219921-72-8 C₈H₆ClF₃N₂O 
• 957111-71-6 3-chloro-N-[(2S)-2-(4-fluorophenyl)-4-hydroxybutyl]-N-methyl-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

ACLY INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDES

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q1, Q2, R1, R2, R3a, R3b, Rsup

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that 13an could be a promising drug candidate for the treatment of TNBC and hence merits further studies.

HYDRAZIDE COMPOUND AND ITS APPLICATION FOR CONTROLLING HARMFUL ARTHROPOD

PROBLEM TO BE SOLVED: To provide a composition having excellent controlling effect on harmful arthropod. SOLUTION: There is provided a hydrazide compound represented by the formula (1), where X1 and X2 are the same or different and represent a halogen atom, R1 represents hydrogen or a methyl group, R2 represents a C1 to C12 chain hydrocarbon group which may have a group selected from a group E1, a C3 to C12 cyclic hydrocarbon group which may have a group selected from a group E2, a 5 to 6-membered hetero cyclic group which may have a group selected from the group E2, an OR3 group, a N(R4)R5 group or a hydrogen atom. The compound has excellent controlling effect on harmful arthropod. COPYRIGHT: (C)2015,JPO&INPIT

PIPERIDINE DERIVATIVE AND USE THEREOF

The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula:wherein R1 is carbamoylmethyl, methylsulfonylethylcarbonyl and the like; R2 is methyl or cyclopropyl; R3 is a hydrogen atom or methyl; R4 is a chlorine atom or trifluoromethyl; R5 is a chlorine atom or trifluoromethyl; and a group represented by the formula:is a group represented by the formula:wherein R6 is a hydrogen atom, methyl, ethyl or isopropyl; R7 is a hydrogen atom, methyl or a chlorine atom; and R8 is a hydrogen atom, a fluorine atom, a chlorine atom or methyl; or 3-methylthiophen-2-yl, and a salt thereof.